CLCF1 and hepatocellular carcinoma: It is reported that there is an uncharacterized mechanism of biochemical resistance to hormone therapies orchestrated by the miR-30a-5p/CLCF1 axis to mediate sorafenib resistance and aerobic glycolysis in HCC, and targeting the miR-30a-5p/CLCF1 axis may contribute for therapeutic HCC sorafenib resistance patients (Zhang et al., 2020).